

PERSONAL INFORMATION Karin Janssen van Doorn

WORK EXPERIENCE

July 2015- Present **Clinical assessor**
FAMHP (Belgium)

September 2008-August 2014 **Staffmember**
UZA Antwerp (Belgium)
Nehrology, Hemodialysis, Peritoneal dialysis, Renal transplantation, stem cell apheresis, Acute Kidney Injury (ICU),

EDUCATION AND TRAINING

September 1989-June 1996 **MD**
Free University of Brussels (Belgium)
Medicine

September 2003-June 2006 **Master**
Free University of Brussels (Belgium)
Ethics

- **PhD in Medical Sciences**
University Antwerp and Brussels (Belgium)
OBSERVATIONAL STUDIES ON
RENAL IMPAIRMENT IN CRITICALLY ILL PATIENTS
3/2016

September 2019-December 2019 **Post Master Course Medical Law.**
Free University of Brussels (Belgium)
Medical Law

ADDITIONAL INFORMATION

Expertise Internal Medicine
Nephrology
Hemodialysis
Peritoneal dialysis
Renal transplantation
Intensive Care
Sepsis
Hematological Stem cells
Hematology
Cystic Fibrosis
Enzyme replacement therapy
Ethics

Publications 1.K. Janssen van Doorn, E. Debing, F. Van Tussenbroeck, A. Goossens, P. Van den Brande and P. Van der Niepen. Unilateral hydronephrosis and recurrent endometrial stromal sarcoma with review of the literature. Acta Clin Belg 1999; 54(3): 165-168.
2.K. Janssen van Doorn, P. Van der Niepen, F. Van Tussenbroeck and D. Verbeelen. Acute tubulo-interstitial nephritis and renal infarction secondary to ergotamine therapy. Nephrol Dial Transpl 2000; 15: 1877-1879.

- 3.K. Janssen van Doorn, M. Diltoer, S. Servotte, K. Jochmans, M. Laubach, M. Keuppens and L. Huyghens. Transfusion of polymerized bovine haemoglobin in a patient with sickle cell anemia and severe allo-immunization: a case report. *Acta Clin Belg* 2001; 56(3): 191-194.
- 4.K. Janssen van Doorn, B. Neyns, P. Van der Niepen and D. Verbeelen. Pamidronate related nephrotoxicity (tubulo-interstitial nephritis) in a patient with osteolytic bone metastases. *Nephron*: 2001; 89: 467-468.
- 5.P. Van der Niepen, K. Janssen van Doorn, K. Van den Houte, D. Verbeelen. Crystalline nephropathy reviewed acute renal failure and nimesulide. *Nephrol Dial Transpl* 2002; 17: 315-316.
- 6.K. Janssen van Doorn, D. Pierard, D. Verbeelen. Typhoid Fever: Letter to the editor. *N Engl J Med* 2003;348(12):1182-1183
- 7.K. Janssen van Doorn, M. Heylen, T. Mets, D. Verbeelen. Evaluation of functional and mental state and Quality of Life in chronic haemodialysis patients. *Int Urol Nephrol* 2004; 36(2): 263-267
- 8.K. Janssen van Doorn, D. Pierard, H. Spapen. Acute renal dysfunction in Salmonella gastroenteritis. *J Clin Gastroenterol* 2006;40(10):910-912
- 9.K. Janssen van Doorn, M. Diltoer and H. Spapen. Do-Not-Resuscitate orders in the critically-ill patient. An observational study with special emphasis on withholding of renal replacement therapy. *Acta Clin Belg.* 2008;63:221-6.
- 10.K. Janssen van Doorn, H. Spapen, C. Geers, M. Diltoer and W Shabana. Sepsis-related acute kidney injury: a protective effect of drotrecogin alfa (activated) treatment? *Acta Anaesthesiol Scand* 2008; 52(9): 1259-64.
- 11.K. Janssen van Doorn. Intensieve Geneeskunde - therapeutisch beleid of therapeutische hardnekkigheid? *NTT* 2009; 63(2):43-54.
- 12.J. Verheyen, T. Vermeulen, K. Janssen van Doorn, C. Vrints, V. Conraads. Treating humo-ral rejection after cardiac transplantation. *Acta Cardiologica* 2011;66(2): 263-266
- 13.H.D. Spapen, K. Janssen van Doorn, M. Diltoer, W. Verbrugghe, R. Jacobs, N. Dobbeleir, P.M. Honore, P.G. Jorens. Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. *Annals Intens Care* 2011, 1:26
15. K. Janssen van Doorn. Levenskunst en hoop, twee revitaliserende factoren. *Filosofie & Praktijk* 2011; 32(3): 36-47.
- 16.H. Spapen, K. Janssen van Doorn. Pulmonary septic shock with or without concomitant acute kidney injury. Does activated protein C make a difference? *Crit Care & Shock* 2011; 14(3): 60-64.
- 17.C. Van Noten, K. Janssen van Doorn, E. Vermander, S. Vlayen, G.A. Verpooten, M.M. Couttenye. Maximal conservative therapy of calcific uremic arteriolopathy. *Clin Nephrol* 2012;(78):61-63.
- 18.S. Vellinga, W. Verbrugghe, R. De Paep, G.A. Verpooten, K. Janssen van Doorn. Identification of Modifiable Risk Factors for Acute Kidney Injury after Cardiac Surgery. *Neth J Med* 2012;70(10):450-4.
- 19.K. Janssen van Doorn, E. Dirinck, G.A. Verpooten, M.M. Couttenye. Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome. *Clinical Kidney Journal* 2013;6:216-219.
- 20.E. Philipse, V. Van Marck, G.A. Verpooten, K. Janssen van Doorn. A patient with oliguria and hemoptysis: do not forget the lung-kidney connection! *Internal and Emergency Medicine*. 2013: may 4.
- 21.S. Vellinga, G.A. Verpooten, K. Janssen van Doorn. Trends in therapeutic plasma-exchange; a single-center evaluation. *Int J Artif Organs* 2013 Nov 20;36(10):730-7
22. A. Verlinden, A. Van de Velde, G.A. Verpooten, K. Janssen van Doorn. Determining factors predictive of CD34+cell collection efficiency in an effort to avoid extended and repeated apheresis sessions. *J Clin Apher.* 2013 Aug 24.
- 23.Karin Janssen van Doorn, Walter Verbrugghe, Kristien Wouters, Hilde Janssens, Philippe G Jorens. The duration of hypotension determines the evolution of bacteremia-induced acute kidney injury in the intensive care unit. *PLOS ONE* 2014 12;9 (12)
24. Karin Janssen van Doorn. Sepsis induced acute kidney injury still remains a challenge. *EMJ* 2017.

Projects Co-investigator in following clinical trials:
Omapatrilat versus amlodipine in essential hypertension

-VALUE

Erythropoetine B: RecoJet(R) versus conventional needle

-CREATE: Recopen

IMPACT: Sirolimus versus Cyclosporine in renal transplantation

CERLO80: Myfortic versus Cellcept in renal transplantation

SHARF: intermittent versus continuous dialysis in acute renal failure (multi-center-study)

NAVIGATOR

Linezolid M/1260/0080: Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the treatment of catheter-related gram-positive bloodstream infections (multi-center-study)

APSEP: Safety and effect of Calf Intestinal Alkaline Phosphatase in patients with sepsis

WELPICUS

PRIMS: Pharmaco-epidemiology Registry Protocol.

STABILO ML21348

MILESTONE: Mid dilution International prospective Study ON outcome.

CAN-004/CANVAS TRIAL: Autologous Dendritic Cells as Treatment in Patients with epithelial ovarian cancer.

SOTIO-DCVAC/PCa in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1stLine Chemotherapy.

Principal investigator in following clinical trials:

LMW-heparin versus unfractionated heparin in continuous hemodialysis (single-center-study)

Drotrecogin (Xigris) versus unfractionated heparin in continuous hemodialysis (single-center-study)

Cognitive functioning disturbing in hemodialysis patients (single-center-study)

Memberships

Member editorial board: 'Tijdschrift voor gezondheidszorg en ethiek'

Other Relevant Information